Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment.

Addressing the significant challenges of treating depression, anxiety, and substance abuse, this Patent Highlight explores the development of innovative small-molecule heterocyclic compounds as Gq-biased agonists of the 5-HT2A receptor. Unlike traditional treatments, these compounds selectively activate 5-HT2A-mediated Gq signaling, excluding related receptors like 5-HT2B and 5-HT2C. This selectivity suggests a more targeted and efficient therapeutic approach. The discovery of these compounds could herald a new era in neuropsychiatric treatment, promising safer, faster, and more effective interventions. Further research will illuminate their potential and applicability in clinical settings.